Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

BACKGROUND: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakita, Daisuke, Nagao, Toshitaka, Takahashi, Hideaki, Kano, Satoshi, Honma, Yoshitaka, Hirai, Hideaki, Saigusa, Natsuki, Akazawa, Kohei, Tani, Kaori, Ojiri, Hiroya, Tsukahara, Kiyoaki, Ozawa, Hiroyuki, Okami, Kenji, Kondo, Takahito, Togashi, Takafumi, Fushimi, Chihiro, Shimura, Tomotaka, Shimizu, Akira, Okamoto, Isaku, Okada, Takuro, Imanishi, Yorihisa, Watanabe, Yoshihiro, Otsuka, Kuninori, Sakai, Akihiro, Ebisumoto, Koji, Sato, Yuichiro, Yamazaki, Keisuke, Ueki, Yushi, Hanazawa, Toyoyuki, Saito, Yuki, Ando, Mizuo, Matsuki, Takashi, Nakaguro, Masato, Sato, Yukiko, Urano, Makoto, Utsumi, Yoshitaka, Kohsaka, Shinji, Saotome, Takashi, Tada, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459484/
https://www.ncbi.nlm.nih.gov/pubmed/36090801
http://dx.doi.org/10.1177/17588359221119538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459484/
https://www.ncbi.nlm.nih.gov/pubmed/36090801
http://dx.doi.org/10.1177/17588359221119538

Ejemplares similares